NeuroVision Imaging receives ADDF funding to develop biomarker tests for Alzheimer s disease
NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer s disease and other forms of dementia and neurodegenerative disorders.
Many of the existing diagnostics tests for Alzheimer s are expensive and invasive, but the ability to detect and measure biomarkers in a blood test could revolutionize the way scientists and clinicians approach the disease. In addition to providing us a better understanding of how the disease progresses, biomarkers will enable us to improve clinical trials and more accurately monitor response to treatments.
E-Mail
SACRAMENTO (Feb. 2, 2021) NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer s disease and other forms of dementia and neurodegenerative disorders. Many of the existing diagnostics tests for Alzheimer s are expensive and invasive, but the ability to detect and measure biomarkers in a blood test could revolutionize the way scientists and clinicians approach the disease, said Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF. In addition to providing us a better understanding of how the disease progresses, biomarkers will enable us to improve clinical trials and more accurately monitor response to treatments.